Vivek Unni, M.D., Ph.D., de Oregon Health & Science University, y sus colegas han descubierto que la proteína alfa sinucleína, que se sabe que se agrupa como “cuerpos de Lewy” en la enfermedad de Parkinson, también desempeña un papel en el melanoma. (OHSU/Christine Torres Hicks)

Tom Sellers, M.D., M.P.H., newly announced director of the OHSU Knight Cancer Institute, introduces himself to the members of the institute. (OHSU).

Brian Druker, M.D., and Tom Sellers, Ph.D., M.P.H. (OHSU)

Researchers at Oregon Health & Science University have identified a gene that could hinder HIV vaccine effectiveness in humans, paving the way for improved vaccine development against HIV and other diseases like cancer and malaria. Klaus Früh's research involves investigating the genetic requirements of rhesus cytomegalovirus (RhCMV) to trigger unique T cell responses, leading to the design of a human CMV-based HIV vaccine that omits inhibitory genes like UL18 to improve immune response efficacy. From left, professors Klaus Früh, Ph.D., VGTI associate director Louis Picker, M.D., and professor Scott Hansen, Ph.D. (OHSU/Christine Torres Hicks) 

Researchers at Oregon Health & Science University have identified a gene that could hinder HIV vaccine effectiveness in humans, paving the way for improved vaccine development against HIV and other diseases like cancer and malaria. (OHSU/Christine Torres Hicks)